Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone45-4444-8888
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$17.72 billion
Profitability
Miscellaneous
Employees43,202
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable
Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions
What is Novo Nordisk A/S's stock symbol?
Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."
How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?
Novo Nordisk A/S declared a special dividend on Thursday, August 9th. Shareholders of record on Monday, August 20th will be paid a dividend of $0.4669 per share on Tuesday, August 28th. This represents a yield of 1.72%. The ex-dividend date of this dividend is Friday, August 17th. View Novo Nordisk A/S's Dividend History.
How will Novo Nordisk A/S's stock buyback program work?
Novo Nordisk A/S declared that its Board of Directors has authorized a share repurchase program on Friday, February 2nd 2018, which permits the company to buyback shares, according to EventVestor. This buyback authorization permits the company to purchase shares of its stock through open market purchases. Stock buyback programs are usually a sign that the company's management believes its shares are undervalued.
How were Novo Nordisk A/S's earnings last quarter?
Novo Nordisk A/S (NYSE:NVO) released its quarterly earnings data on Friday, February, 1st. The company reported $0.54 EPS for the quarter, missing the consensus estimate of $0.57 by $0.03. The firm had revenue of $4.55 billion for the quarter, compared to analysts' expectations of $4.36 billion. Novo Nordisk A/S had a net margin of 34.67% and a return on equity of 80.45%. View Novo Nordisk A/S's Earnings History.
When is Novo Nordisk A/S's next earnings date?
What guidance has Novo Nordisk A/S issued on next quarter's earnings?
Novo Nordisk A/S updated its FY 2019 earnings guidance on Friday, February, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $17.446-17.949 billion, compared to the consensus revenue estimate of $17.91 billion.
What price target have analysts set for NVO?
15 brokerages have issued 1-year price objectives for Novo Nordisk A/S's stock. Their predictions range from $48.61 to $48.61. On average, they expect Novo Nordisk A/S's stock price to reach $48.61 in the next twelve months. This suggests that the stock has a possible downside of 7.1%. View Analyst Price Targets for Novo Nordisk A/S.
What is the consensus analysts' recommendation for Novo Nordisk A/S?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 2 sell ratings, 6 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novo Nordisk A/S.
Has Novo Nordisk A/S been receiving favorable news coverage?
Media stories about NVO stock have been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Novo Nordisk A/S earned a news impact score of 1.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days.
Who are some of Novo Nordisk A/S's key competitors?
Some companies that are related to Novo Nordisk A/S include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), AbbVie (ABBV), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG) and Shire (SHPG).
What other stocks do shareholders of Novo Nordisk A/S own?
Who are Novo Nordisk A/S's key executives?
Novo Nordisk A/S's management team includes the folowing people:
- Lars Fruergaard Jørgensen, President & Chief Executive Officer
- Maziar Mike Doustdar, Executive Vice President-International Operations
- Karsten Munk Knudsen, Chief Financial Officer & Executive Vice President
- Mads Krogsgaard Thomsen, Chief Science Officer & Executive Vice President
- Alan C. Moses, Senior Vice President & Chief Medical Officer
Who are Novo Nordisk A/S's major shareholders?
Novo Nordisk A/S's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.58%), Bank of America Corp DE (0.48%), BlackRock Inc. (0.35%), Folketrygdfondet (0.23%), Sustainable Growth Advisers LP (0.15%) and FMR LLC (0.10%). View Institutional Ownership Trends for Novo Nordisk A/S.
Which major investors are selling Novo Nordisk A/S stock?
NVO stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, BlackRock Inc., First Trust Advisors LP, PNC Financial Services Group Inc., Connor Clark & Lunn Investment Management Ltd., Sustainable Growth Advisers LP, Stifel Financial Corp and Bank of New York Mellon Corp. View Insider Buying and Selling for Novo Nordisk A/S.
Which major investors are buying Novo Nordisk A/S stock?
NVO stock was bought by a variety of institutional investors in the last quarter, including Boston Partners, Fisher Asset Management LLC, Avalon Advisors LLC, Two Sigma Advisers LP, CIBC Asset Management Inc, NorthCoast Asset Management LLC, Northern Trust Corp and Canada Pension Plan Investment Board. View Insider Buying and Selling for Novo Nordisk A/S.
How do I buy shares of Novo Nordisk A/S?
Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novo Nordisk A/S's stock price today?
One share of NVO stock can currently be purchased for approximately $52.30.
How big of a company is Novo Nordisk A/S?
Novo Nordisk A/S has a market capitalization of $127.80 billion and generates $17.72 billion in revenue each year. The company earns $5.91 billion in net income (profit) each year or $2.52 on an earnings per share basis. Novo Nordisk A/S employs 43,202 workers across the globe.
What is Novo Nordisk A/S's official website?
How can I contact Novo Nordisk A/S?
Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]
MarketBeat Community Rating for Novo Nordisk A/S (NYSE NVO)
MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote "Outperform" if you believe NVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
